Cutler Group LP Galectin Therapeutics Inc Call Options Transaction History

Cutler Group LP

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 04, 2022	SELL	$1.19 - $1.74 $476 - $696	-400 Closed	0 $0
Q1 2022 Apr 14, 2022	SELL	$1.61 - $2.31 $3,059 - $4,389	-1,900 Reduced 82.61%	400 $0
Q4 2021 Jan 18, 2022	SELL	$2.07 - $3.8 $19,665 - $36,100	-9,500 Reduced 80.51%	2,300 $0
Q3 2021 Oct 26, 2021	BUY	$2.59 - $4.15 $30,562 - $48,970	11,800 New	11,800 $2,000
Q2 2018 Aug 10, 2018	SELL	$3.16 - $9.16 $1,896 - $5,496	-600 Closed	0 $0
Q1 2018 May 11, 2018	SELL	$3.78 - $5.97 $6,048 - $9,552	-1,600 Reduced 72.73%	600 $1,000
Q4 2017 Jan 17, 2018	SELL	$1.54 - $3.34 $2,772 - $6,012	-1,800 Reduced 45.0%	2,200 $5,000
Q3 2017 Oct 17, 2017	BUY	$1.67 - $2.3 $6,680 - $9,200	4,000	4,000 $1,000

9.65M

1.16M

1.98M

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $123M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.